KR20230045095A - Bcma와 결합하는 단일 가변 도메인 및 항원 결합 분자 - Google Patents

Bcma와 결합하는 단일 가변 도메인 및 항원 결합 분자 Download PDF

Info

Publication number
KR20230045095A
KR20230045095A KR1020237008715A KR20237008715A KR20230045095A KR 20230045095 A KR20230045095 A KR 20230045095A KR 1020237008715 A KR1020237008715 A KR 1020237008715A KR 20237008715 A KR20237008715 A KR 20237008715A KR 20230045095 A KR20230045095 A KR 20230045095A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
variable domain
single variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237008715A
Other languages
English (en)
Korean (ko)
Inventor
지팽 젠
메이주안 시에
시우젠 두
이민 마
빙 장
통지에 수
시츄안 장
Original Assignee
치아타이 티안큉 파마수티컬 그룹 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치아타이 티안큉 파마수티컬 그룹 주식회사 filed Critical 치아타이 티안큉 파마수티컬 그룹 주식회사
Publication of KR20230045095A publication Critical patent/KR20230045095A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237008715A 2020-08-20 2021-08-16 Bcma와 결합하는 단일 가변 도메인 및 항원 결합 분자 Pending KR20230045095A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010842501.X 2020-08-20
CN202010842501 2020-08-20
PCT/CN2021/112758 WO2022037528A1 (zh) 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子

Publications (1)

Publication Number Publication Date
KR20230045095A true KR20230045095A (ko) 2023-04-04

Family

ID=80323414

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237008715A Pending KR20230045095A (ko) 2020-08-20 2021-08-16 Bcma와 결합하는 단일 가변 도메인 및 항원 결합 분자

Country Status (6)

Country Link
US (1) US20230265181A1 (https=)
EP (1) EP4201960A4 (https=)
JP (1) JP7821161B2 (https=)
KR (1) KR20230045095A (https=)
CN (1) CN115698077A (https=)
WO (1) WO2022037528A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117062840A (zh) * 2021-04-15 2023-11-14 正大天晴药业集团股份有限公司 靶向bcma的多特异性抗体
WO2025098446A1 (zh) * 2023-11-07 2025-05-15 赛斯尔擎生物技术（上海）有限公司 抗bcma单域抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2406284B9 (en) * 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
IL271194B2 (en) * 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
AU2019214183B2 (en) * 2018-02-01 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
CN109942708B (zh) 2019-03-28 2021-01-05 上海科棋药业科技有限公司 一种抗bcma的单域抗体及其应用
CN109942709B (zh) 2019-04-22 2019-12-27 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
CN117062840A (zh) * 2021-04-15 2023-11-14 正大天晴药业集团股份有限公司 靶向bcma的多特异性抗体

Also Published As

Publication number Publication date
US20230265181A1 (en) 2023-08-24
JP7821161B2 (ja) 2026-02-26
EP4201960A1 (en) 2023-06-28
EP4201960A4 (en) 2024-09-04
JP2023539453A (ja) 2023-09-14
CN115698077A (zh) 2023-02-03
WO2022037528A1 (zh) 2022-02-24

Similar Documents

Publication Publication Date Title
JP7097364B2 (ja) グレムリン－１の結晶構造及び阻害抗体
JP7820383B2 (ja) グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
EP3744734A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
CN109721656B (zh) 靶向rankl的治疗性抗体
JP2024023278A (ja) Ａｌｋ７結合タンパク質およびその使用
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
JP2024541882A (ja) ｃ－Ｍｅｔに結合する抗体及びその使用
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
JP7821161B2 (ja) Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
JP2020524988A (ja) 抗ｒｏｂｏ２抗体、組成物、方法、およびその使用
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP7821159B2 (ja) Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
KR20230035079A (ko) 응고인자 xi(fxi) 결합 단백질
US12612635B2 (en) BCMA-binding single variable structural domain and antigen-binding molecule
AU2021242976B2 (en) Antibodies against AREG and its use
TWI889920B (zh) 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途
CN110407942B (zh) 针对kn044的单域抗体
JP2010533732A (ja) プロテアーゼ活性化受容体−１（ｐａｒ１）のアンタゴニスト抗体
WO2023092327A1 (en) Vegf-binding protein and use thereof
AU2024319932A1 (en) Btn3a-binding protein and medical uses thereof
JP2026504831A (ja) ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及びそれらの医薬的使用
CN116478288A (zh) 红细胞弱结合型人源化cd47抗体及其应用
TW202432593A (zh) 抗體、其抗原結合片段及其藥物用途
JP2024544961A (ja) 抗ｃｌｄｎ１８．２モノクローナル抗体およびその使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230313

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240816

Comment text: Request for Examination of Application